Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and 5-FU/LV in Gastric or GE Junction Adenocarcinoma
NCT00103103Phase 2Terminated
- Sponsor
- California Cancer Consortium
- Start
- Mar 2005
- Primary completion
- Aug 2005
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by California Cancer Consortium. Primary endpoint: Overall Response Rate. Started Mar 2005; status: terminated.
02
Drugs
bortezomib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00103103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103103.